Belfast Health and Social Care Trust
caring supporting improving together

FOI/38302

12 October 2026

Multiple Sclerosis Biological Treatments

Dear Belfast Health and Social Care Trust,

Q1. How many patients received treatment for any condition in the last six months with any of the following treatment regimens (March 2026 – August 2026)?

- **Ocrevus (ocrelizumab) IV** 173
- **Ocrevus (ocrelizumab) Subcutaneous** 91
- **Kesimpta (ofatumumab)** 50
- **Briumvi (ublituximab)** 0
- **Mavenclad (cladribine)** <5
- **Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic)** 255
- **Vumerity (diroximel fumarate)** 35
- **Tysabri (natalizumab) IV** 39
- **Tysabri (natalizumab) Subcutaneous** 48
- **Tyruko (natalizumab biosimilar)** 0
- **Any Other Platform Therapies (interferon Beta, peginterferon beta-1a, teriflunomide, glatiramoids)** 201
- **S1P Receptor Modulators (fingolimod, siponimod, ponesimod, ozanimod)** 62

Q1a. Of the patients identified in question one, how many of the same patients received treatment with each treatment regimen in November 2025-April 2026 AND March 2026 – August 2026)?

- **Ocrevus (ocrelizumab) IV** 163
- **Ocrevus (ocrelizumab) Subcutaneous** 78
- **Kesimpta (ofatumumab)** 47
- **Briumvi (ublituximab)** 0
- **Mavenclad (cladribine)** <5
- **Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic)** 252
- **Vumerity (diroximel fumarate)** 30
- **Tysabri (natalizumab) IV** 39
- **Tysabri (natalizumab) Subcutaneous** 44
- **Tyruko (natalizumab biosimilar)** 0
- **Any Other Platform Therapies (interferon Beta, peginterferon beta-1a, teriflunomide, glatiramoids)** 194
- **S1P Receptor Modulators (fingolimod, siponimod, ponesimod, ozanimod)** 61

We are unable to provide an exact figure where numbers are very low, <5. To provide this level of information would reduce numbers to discoverable limits where the patients could be identifiable. This is because many of these drugs are high cost and prescribed on a named patient basis. Pharmaceutical companies would be aware of this.

This is exempt from release under section 40(2) Personal Information relating to a third party of the FOI Act.

Disclosure would constitute a breach of the principles of the Data Protection Act 2018.